Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 10;8(34):57680-57692.
doi: 10.18632/oncotarget.17016. eCollection 2017 Aug 22.

Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies

Qing-Ge Zhu #  1 , Shi-Ming Zhang #  1 , Xiao-Xiao Ding #  1 , Bing He  1 , Hu-Qin Zhang  1
Affiliations
Review

Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies

Qing-Ge Zhu et al. Oncotarget. .

Abstract

Lung cancer is one of the most common causes of cancer-related death in the world. The large number of lung cancer cases is non-small cell lung cancer (NSCLC), which approximately accounting for 75% of lung cancer. Over the past years, our comprehensive knowledge about the molecular biology of NSCLC has been rapidly enriching, which has promoted the discovery of driver genes in NSCLC and directed FDA-approved targeted therapies. Of course, the targeted therapies based on driver genes provide a more exact option for advanced non-small cell lung cancer, improving the survival rate of patients. Now, we will review the landscape of driver genes in NSCLC including the characteristics, detection methods, the application of target therapy and challenges.

Keywords: characteristics; detection methods; driver genes; non-small cell lung cancer; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST There are no potential conflicts of interest.

Figures

Figure 1
Figure 1. Several RTK subgroups
(A) EGF receptor EGF, HER2 encode the proteins belonging to EGF receptor; (B) IGF-1 receptor ALK, ROS1 encode the proteins belonging to IGF-1 receptor; (C) PDGF receptor PDGFRA encode the proteins belonging to PDGF receptor; (D) FGF receptor FGF encodes the protein belonging to FGF receptor.
Figure 2
Figure 2. Pathways mediated by RTKs
See this image and copyright information in PMC

References

    1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23:3175–85. doi: 10.1200/JCO.2005.10.462. - DOI - PubMed
    1. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch VW, Vansteenkiste JF, Watanabe H, Wu YL, Zielinski M, Ball D, Rami-Porta R, International Association for the Study of Lung Cancer S, Prognostic Factors Committee ABM, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10:1675–84. doi: 10.1097/JTO.0000000000000678. - DOI - PubMed
    1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28. doi: 10.1056/NEJMoa1501824. - DOI - PubMed
    1. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:2537–9. doi: 10.1056/NEJMc1404894. - DOI - PubMed
    1. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71. doi: 10.1056/NEJMoa1406766. - DOI - PMC - PubMed